American Journal of Psychiatry
June 3, 2026
D. D'Souza, J. Cortes-Briones, Justin Raj et al.
OBJECTIVE Cannabis use is a known risk factor for psychosis, but it remains unclear whether cannabis-associated psychosis (CAP) differs meaningfully from non-cannabis-associated psychosis (NCAP) in clinical presentation, biology, or illness course. The objective of this study was to characterize the presentation and course of first-episode psychosis with and without cannabis exposure. METHODS...
World Journal of Biological Psychiatry
March 22, 2022
Deepak C. D’Souza, M. Diforti, Suhas Ganesh et al.
Abstract Objectives The liberalisation of cannabis laws, the increasing availability and potency of cannabis has renewed concern about the risk of psychosis with cannabis. Methods The objective of the WFSBP task force was to review the literature about this relationship. Results Converging lines of evidence suggest that exposure to cannabis increases the risk for psychoses ranging from...
medRxiv
January 31, 2022
Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al.
preprint
Abstract Introduction Cannabis use has been associated with several psychosis outcomes including acute and persistent psychosis termed Cannabis Induced Psychotic Disorder (CIPD). The clinical and cognitive profile, course of CIPD, and the extent to which it is different from psychosis unrelated to cannabis exposure (PsyNoCan) is not clear. Methods The acute presentation and short-term (∼4...
Psychological Medicine
October 16, 2019
Deepak C. D’Souza, Suhas Ganesh, Jose A Cortes-Briones et al.
Abstract Background The literature on psychosis-relevant outcomes in cannabis users does not adequately address the confounding effects of other substance use/misuse and psychiatric disorders. Methods We studied a unique population for whom cannabis use is central and necessary to their way of life. They are forbidden from using other substances, including tobacco and alcohol. Their use of...
Uri Bright, Suhas Ganesh, Daniel F. Levey et al.
Abstract Background Cannabis is one of the most widely used psychoactive substances worldwide. Δ 9 -tetrahydrocannabinol (Δ 9 -THC) is the main contributor to cannabis-induced effects such as euphoria, anxiety, and psychotomimetic effects, and is metabolized by several hepatic enzymes, including CYP3A4. There are interindividual differences in how cannabis affects users, which have substantial...